← Human Trials & Peer-Reviewed Studies
Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial
Plain-language guide to PMID 34490741 (2022): double-blind randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 34490741
- Journal
- Diabetes, obesity & metabolism
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Heimburger SMN et al. (7 authors)
- DOI
- 10.1111/dom.14545
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
Glucose-dependent insulinotropic polypeptide (GIP) plays an important role in the glucose and lipid metabolism.
The researchers investigated the effects of exogenous GIP on lipid metabolism during time of stable insulin levels.
Who Took Part
The age groups tagged for this paper are young adults and adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on GIP (Gastric Inhibitory Polypeptide), so expectations could not easily colour the readings.
Some participants received a placebo instead of GIP (Gastric Inhibitory Polypeptide), giving a reference point.
In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.
What Was Measured
The researchers investigated the effects of exogenous GIP on lipid metabolism during time of stable insulin levels.
The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Gastric Inhibitory Polypeptide, Glucose, Hyperglycemia, Insulin and Lipolysis.
Author keywords: GIP, antidiabetic drug, incretin physiology, insulin therapy, lipid-lowering therapy and type 1 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide).
The publication is from 2022 (Diabetes, obesity & metabolism), a journal based in England.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.